16. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci.
1997 86(1):1–12.
17. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals.
J Clin Pharmacol. 2002;42:620–643.
18. Kalorama Information. Drug delivery markets, 2nd ed., vol II: Implantable/injectable delivery systems. Kalorama Information,
Rockville, MD; 2007.
19. Francis GE, Fisher D, Delgado C, Malik F, Gardiner A, Neale D. PEGylation of cytokines and other therapeutic proteins
and peptides: the importance of biological optimisation of coupling techniques. Int. J Hematol. 1998;68(1):1–18.
20. Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Disc. 2003;2:215–221.
21. Lambert WJ, Los KDA. DepoFoam multivesicular liposomes for the sustained release of macromolecules in modified release
drug delivery technology, 2nd ed., accepted.
22. Wilkinson et al. Method and device for intradermally delivering a substance. United States patent US 7,115,108. 2002
Apr 2.
23. Horspool KR, Lipinski CA. Advancing new drug delivery concepts to gain the lead. Drug Delivery Technol. 2003;3(7):34–46.
24. Bookbinder et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Cont Release. 2006;
114:230–241.
25. Raviv U, Needleman DJ, Li Y, Miller HP, Wilson L, Safinya CR. Cationic liposome-microtubule complexes: pathways to the
formation of two-state lipid-protein nanotubes with open or closed ends. PNAS. 2005;102(32):11167.
26. Prescott JH, Lipka S, Baldwin S, Sheppard NF, Maloney JM, Coppeta J, Yomtov B, Staples, MA, Santini, JT. Chronic, programmed
polypeptide delivery from an implanted, multireservoir microchip device. Nature Biotechnol. 2006; 24:437–438.
27. Mastrobattista E, van der Aa, MAEM, Hennink WE, Crommelin DJA. Artificial viruses: a nanotechnological approach to gene
delivery. Nature Rev Drug Disc. 2006;(5):115–121.
28. Hackett CJ, Harn DA. Vaccine adjuvants: immunological and clinical principles. Totowa, NJ: Humana Press; 2006.
29. Degen WGJ, Jansen T, Schijns VEJC. Vaccine adjuvant technology: from mechanistic concepts to practical applications.
Expert Rev Vaccines. 2003;2(2):327–335.
30. Alving CR. Design and selection of vaccine adjuvants: animal models and human trials Vaccine. 2002;20(Supplement 3):
S56–S64.
31. Jäger E, Jäger D, Knuth A. Antigen-specific immunotherapy and cancer vaccines. Int J Cancer. 2003;106(6):817–820.
32. Scanlan MJ, Jäger D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. 2001;3:95–98.
33. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Disc. 2004 Aug;3:711–716.
34. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics:
a review. J Control Release. 2000;65(1–2): 271–84.
35. Kaul G, Amiji M. Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm
Res. 2002; 19(7):1061–1067.
36. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988 332:323-327.
37. Lenehan P, Gliklich RE, Worzel B, Freshley J. Rescuing drugs through personalized medicine. Applied Clin Trials. 2005
April 2 supplement:22–26.
38. Lian T, Ho, RJY. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001;90:667–680.
39. Hu H, Chen D, Liu Y, Deng Y, Yang S, Qiao M, Zhao J, Zhao X. Target ability and therapy efficacy of immunoliposomes using
a humanized antihepatoma disulfide-stabilized Fv fragment on tumor cells. J Pharm Sci. 2006;(95):192–199.
40. Pardridge, WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem. 1998;70(5):1781–92.
41. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2000;3(2):90–105.
|
